We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Features of Neuromyelitis Optica Spectrum Disorders and Aquaporin-4 With Myelin-Oligodendrocyte Glycoprotein Antibodies—Reply

Joanna Kitley, BMBS1; Patrick Waters, PhD1; Angela Vincent, FRS1; Jacqueline Palace, DM1
[+] Author Affiliations
1Nuffield Department of Clinical Neurosciences, Oxford University Hospitals NHS Trust, University of Oxford, Oxford, England
JAMA Neurol. 2014;71(7):924. doi:10.1001/jamaneurol.2014.940.
Text Size: A A A
Published online


In Reply We thank Gao and colleagues for their comments regarding our article.1 We agree that the spectrum of neuromyelitis optica (NMO) is much wider than originally thought and that it is now recognized that the term NMO is not synonymous with aquaporin-4 antibody (AQP4-Ab) disease. In our experience, the presence of AQP4-Ab indicates a generally severe, frequently relapsing central nervous system inflammatory disease and we manage AQP4-Ab–positive patients with early and long-term immunosuppression regardless of the clinical phenotype. Conversely, patients referred to our UK AQP4-Ab assay service and those seen within our specialist clinical NMO service are a heterogeneous group, despite many having features considered typical of NMO such as longitudinally extensive transverse myelitis or severe/bilateral optic neuritis. We consider AQP4-Ab–negative patients separately from those with AQP4-Ab, even if fulfilling diagnostic criteria for NMO. In general, we treat such patients less aggressively but their management is difficult because of the clinical heterogeneity. Myelin-oligodendrocyte glycoprotein Abs appear to offer an alternative biomarker in patients presenting with features of NMO and its spectrum who are negative for AQP4-Ab and this biomarker appears to be helpful in making decisions regarding patient management and prognosis. We agree that the current NMO diagnostic criteria need updating to reflect the fact that AQP4-Ab–negative NMO/NMO spectrum disorder is not a clear entity and that such patients should be considered separately from those with AQP4-Ab disease.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





July 1, 2014
Jiguo Gao, MD; Wei Pan, MD; Hongliang Zhang, MD, PhD
1Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China2Department of Neurology, The Second Part, The First Hospital of Jilin University, Changchun, China
3School of Public Health, Jilin University, Changchun, China
1Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China
JAMA Neurol. 2014;71(7):923-924. doi:10.1001/jamaneurol.2014.764.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...